PIK3CA in colorectal cancer

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  Cathomas, Gieri ^a  

^a Institut für Pathologie Kantonsspital Baselland   (Switzerland)

Author keywords

Adjuvant therapy; Aspirin; Biomarker; Colorectal cancer; EGFR; PIK3CA; Prediction; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN; PROSTAGLANDIN H2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; ROFECOXIB; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DISEASE FREE SURVIVAL; GENE; GENE MUTATION; HUMAN; MOLECULAR BIOLOGY; PIK3CA GENE; PREDICTION; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84901036853     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00035     Document Type: Short Survey

References (46)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 127:2893-917. doi: 10.1002/ijc.25516.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell (1996) 87:159-70. doi:10.1016/S0092-8674(00)81333-1.
3. Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, et al. Individualized therapy for metastatic colorectal cancer. J Intern Med (2013) 274:1-24. doi:10.1111/joim.12070.
4. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 360:1408-17. doi:10.1056/NEJMoa0805019.
5. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 26:1626-34. doi:10.1200/JCO.2007.14.7116.
6. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 2:489-501. doi:10.1038/nrc839.
7. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 64:7678-81. doi:10.1158/0008-5472.CAN-04-2933.
8. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 304:554. doi:10.1126/science.1096502.
9. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 9:550-62. doi:10.1038/nrc2664.
10. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, et al. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology (2010) 56:229-39. doi:10.1111/j.1365-2559.2009.03468.x.
11. Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, Wakasugi T, et al. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol (2008) 8:56. doi:10.1186/1471-230X-8-56.
12. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene (2013). doi:10.1038/onc.2013.244.
13. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 367:1596-606. doi:10.1056/NEJMoa1207756.
14. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 27:1477-84. doi:10.1200/JCO.2008.18.6544.
15. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia (2008) 10:534-41. doi:10.1593/neo.08336.
16. Iida S, Kato S, Ishiguro M, Matsuyama T, Ishikawa T, Kobayashi H, et al. PIK3CA mutation and methylation influences the outcome of colorectal cancer. Oncol Lett (2012) 3:565-70. doi:10.3892/ol.2011.544.
17. Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta (2012) 413:1605-11. doi:10.1016/j.cca.2012.04.029.
18. Mouradov D, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY, et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol (2013) 108:1785-93. doi:10.1038/ajg.2013.292.
19. Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One (2013) 8:e65479. doi:10.1371/journal.pone.0065479.
20. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res (2013) 19:3285-96. doi:10.1158/1078-0432.CCR-12-3614.
21. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 18:2257-68. doi:10.1158/1078-0432.CCR-11-2410.
22. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 11:753-62. doi:10.1016/S1470-2045(10)70130-3.
23. Phipps AI, Makar KW, Newcomb PA. Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. Int J Colorectal Dis (2013) 28:1637-42. doi:10.1007/s00384-013-1715-8.
24. Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer (2013) 108:2153-63. doi:10.1038/bjc.2013.212.
25. Farina Sarasqueta A, Zeestraten EC, van Wezel T, van Lijnschoten G, van Eijk R, Dekker JW, et al. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol (Dordr) (2011) 34:523-31. doi:10.1007/s13402-011-0054-4.
26. Muller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS, Kawamata N, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res (2007) 31:27-32. doi:10.1016/j.leukres.2006.04.011.
27. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol (2008) 15:1064-9. doi:10.1245/s10434-007-9751-7.
28. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res (2009) 15:5049-59. doi:10.1158/1078-0432.CCR-09-0632.
29. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 105:2652-7. doi:10.1073/pnas.0712169105.
30. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2005) 23:8664-70. doi:10.1200/JCO.2005.01.6071.
31. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 351:337-45. doi:10.1056/NEJMoa033025.
32. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol (2009) 27:2091-6. doi:10.1200/JCO.2009.21.9170.
33. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 369:1023-34. doi:10.1056/NEJMoa1305275.
34. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 69:1851-7. doi:10.1158/0008-5472.CAN-08-2466.
35. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2009) 20:84-90. doi:10.1093/annonc/mdn541.
36. Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer (2012) 11:143-50. doi:10.1016/j.clcc.2011.12.001.
37. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res (2009) 15:3184-8. doi:10.1158/1078-0432.CCR-08-2961.
38. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 348:891-9. doi:10.1056/NEJMoa021735.
39. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 376:1741-50. doi:10.1016/S0140-6736(10)61543-7.
40. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 9:259-67. doi:10.1038/nrclinonc.2011.199.
41. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 302:649-58. doi:10.1001/jama.2009.1112.
42. Peng L, Zhou Y, Wang Y, Mou H, Zhao Q. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature. PLoS One (2013) 8:e58891. doi:10.1371/journal.pone.0058891.
43. Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene (2000) 19:5517-24. doi:10.1038/sj.onc.1203952.
44. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol (2012) 10:575-82. doi:10.1038/nrmicro2819.
45. Gil-Bernabe AM, Lucotti S, Muschel RJ. Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol (2013) 162:433-41. doi:10.1111/bjh.12381.
46. Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol (2013) 31:4297-305. doi:10.1200/JCO.2013.50.0322.